Acute lymphoblastic leukemia Doctors Abroad — Page 3

Dr. Ofer Spielberg is a specialized oncohematologist, focusing on blood cancers like leukemia.

• Practices at Assuta Medical Center
• Expertise in oncohematology, the field dedicated to blood cancers
• Provides targeted treatment for acute lymphoblastic leukemia

Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.

• Named among Israel’s Best Doctors by Forbes for 2025 and 2026.
• Authored over 250 scientific papers on cellular therapies and transplantation.
• Provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.

• Authored over 130 scientific publications on hemato-oncology and cellular therapy.
• Pioneered the integration of CAR-T cell therapy for lymphoma and myeloma.
• Leads allogeneic and autologous bone marrow transplantation programs.
• Served as the Chairman of the Israeli Lymphoma Study Group.

Dr. Hila Magen is a leading Israeli hemato-oncologist at Sheba Medical Center. She heads the Multiple Myeloma and Amyloidosis Unit. Dr. Magen specializes in treating complex plasma cell disorders and high-risk myeloma. She is a principal investigator for innovative point-of-care CAR-T therapy programs. Her work brings advanced immunotherapies into routine clinical care.

• Authored over 100 scientific publications and landmark myeloma studies.
• Completed fellowships at MD Anderson and University of Arkansas for Medical Sciences.
• Performs CAR-T cell therapy and bone marrow transplantations.
• Works at Sheba Medical Center, ranked 7th worldwide in 2026 by Newsweek.

Recognized by Forbes as one of the best doctors in 2018 – Dr. Stepensky has performed over 3,500 bone marrow transplants at Hadassah Medical Center.

• 28 years specializing in pediatric bone marrow transplants
• Focused on rare blood cancer diseases in children
• Known among patients as 'the one who transplants life'
• Leads a dedicated pediatric hematology unit

Dr. Iris Kventsel is a pediatric hemato-oncologist and bone marrow transplant specialist at Sheba Medical Center. She treats childhood sarcomas like Ewing sarcoma and osteosarcoma at the Edmond and Lily Safra Children’s Hospital. Dr. Kventsel integrates targeted therapies with cellular treatments for complex childhood cancers. She serves on the academic staff at Tel Aviv University Faculty of Medicine.

• Specializes in bone marrow transplantation and CAR T-cell therapy for pediatric patients.
• Researches genetic cancer predisposition, including Li-Fraumeni syndrome and susceptibility genes.
• Published in major journals on stem cell biology and surgical oncology (HIPEC).
• Works at Sheba Medical Center, ranked among the world’s top 10 hospitals.

Dr. Elad Jacoby is a pioneer of pediatric CAR T–cell therapy in Israel. He heads the Pediatric Cell Therapy Center at Sheba Medical Center. Dr. Jacoby specializes in treating relapsed and high-risk pediatric leukemias and lymphomas. He completed fellowships at Johns Hopkins and the U.S. National Cancer Institute.

• Medical Director of the Advanced Biotherapy Center at Sheba Medical Center.
• Authored over 240 scientific publications in pediatric hemato-oncology.
• Board-certified in both Pediatrics and Pediatric Hematology and Oncology.
• Leads the integration of CAR T–cell therapy with bone marrow transplantation.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Globally recognized leader in chronic lymphocytic leukemia (CLL) and lymphomas – Dr. Bosch pioneers new treatments and molecular research at Hospital Quiron Barcelona.

• Leads over 80 clinical trials, from phase 1 to phase 3
• Published 100+ studies in top journals like NEJM and Nature Medicine
• Heads Spanish CLL research group and clinical trials
• Post-doctoral fellowship at Columbia University's Institute of Cancer Genetics

Head of Hematology at Hadassah Medical Center – Professor Ben-yehuda pioneered gene therapy and bone marrow transplants for acute lymphoblastic leukemia.

• Trained at Memorial Sloan-Kettering Cancer Center in New York
• First female Dean of Hadassah School of Medicine
• Specializes in molecular diagnostics and immunology
• Recipient of the Healing with the Heart Award for exceptional patient care

Professor Zila Zuckerman specializes in hematology and transplantology at Rambam Medical Center.

• Expert in treating acute lymphoblastic leukemia
• Specializes in transplantology for blood disorders
• Professor with extensive academic and clinical experience

Prof. Elke Jaeger is one of Germany's top oncologists according to Focus rating – she leads Oncology and Hematology at Nordwest Clinic.

• Specializes in sarcoma treatment
• 41 years of oncology experience
• Head of Oncology and Hematology department

Head of Hematology at Nordwest Clinic with 36 years of experience – Dr. Weidmann specializes in blood disorder treatments.

• Focuses on non-Hodgkin lymphoma cases
• Professor with extensive academic and clinical background
• Leads a dedicated hematology sector

Associate Professor in Hematology with 50+ publications – Dr. Eren specializes in blood disorders at Biruni University Hospital.

• Completed Hematology subspecialty training at Istanbul Training and Research Hospital
• Member of European Society of Hematology and Turkish Hematology Association
• Recipient of Young Researcher Award at National Hematology Congress
• Fluent in English for international patient consultations

Dr. Apak specializes in pediatric hematology-oncology with over 26 years of experience, focusing on acute lymphoblastic leukemia at Biruni University Hospital.

• Expert in bone marrow transplantation and CAR T-cell therapy
• Authored 75 international publications in pediatric oncology
• Head of Pediatric Hematology-Oncology Division at Istanbul University-Cerrahpaşa
• Member of Turkish Pediatric Society and Turkish Adolescent Association

Professor Fabio Ciceri leads pioneering cell and gene therapy trials for Acute lymphoblastic leukemia at San Raffaele Hospital.

• Head of Hematology and Bone Marrow Transplantation Unit
• Principal Investigator in clinical trials for hematological cancers
• Published over 180 scientific papers
• Member of European Blood and Marrow Transplantation Group

Head of one of Italy's largest bone marrow transplant departments – Dr. Peccatori oversees 90+ allogeneic transplants annually at San Raffaele.

• 29 years of experience in hematology and bone marrow transplantation
• Author of 70+ studies on leukemia, myeloma, and transplantation
• Specializes in allogeneic transplants for acute leukemias
• Member of European and Italian transplant societies
• Performed 900+ treatments including complex cases

Specializes in acute leukemia and stem cell transplantation – Professor Omay brings 36 years of hematology expertise from Turkey's top institutions.

• Head of Hematology Department at Emsey Hospital
• Trained in molecular hematology at Japan's Mie Medical School
• Published 65+ scientific articles on hematology treatments
• Performs both autologous and allogeneic stem cell transplants